Letter to the Editor
Long-term efficacy of rituximab in chronic ataxic neuropathy associated with anti-ganglioside antibodies
Eficacia a largo plazo del rituximab en la neuropatía crónica atáxica con anticuerpos antigangliósidos
Read
4728
Timeswas read the article
922
Total PDF
3806
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 32 | 12 | 44 |
| 2025 11 | 106 | 91 | 197 |
| 2025 10 | 113 | 56 | 169 |
| 2025 9 | 94 | 91 | 185 |
| 2025 8 | 99 | 79 | 178 |
| 2025 7 | 116 | 20 | 136 |
| 2025 6 | 90 | 12 | 102 |
| 2025 5 | 93 | 21 | 114 |
| 2025 4 | 72 | 18 | 90 |
| 2025 3 | 85 | 12 | 97 |
| 2025 2 | 108 | 12 | 120 |
| 2025 1 | 63 | 14 | 77 |
| 2024 12 | 56 | 9 | 65 |
| 2024 11 | 52 | 5 | 57 |
| 2024 10 | 71 | 20 | 91 |
| 2024 9 | 67 | 17 | 84 |
| 2024 8 | 58 | 18 | 76 |
| 2024 7 | 52 | 4 | 56 |
| 2024 6 | 86 | 13 | 99 |
| 2024 5 | 85 | 4 | 89 |
| 2024 4 | 83 | 8 | 91 |
| 2024 3 | 97 | 17 | 114 |
| 2024 2 | 161 | 25 | 186 |
| 2024 1 | 104 | 15 | 119 |
| 2023 12 | 109 | 15 | 124 |
| 2023 11 | 80 | 15 | 95 |
| 2023 10 | 116 | 14 | 130 |
| 2023 9 | 62 | 4 | 66 |
| 2023 8 | 57 | 10 | 67 |
| 2023 7 | 83 | 6 | 89 |
| 2023 6 | 41 | 8 | 49 |
| 2023 5 | 174 | 13 | 187 |
| 2023 4 | 64 | 8 | 72 |
| 2023 3 | 127 | 9 | 136 |
| 2023 2 | 50 | 14 | 64 |
| 2023 1 | 77 | 16 | 93 |
| 2022 12 | 59 | 5 | 64 |
| 2022 11 | 67 | 9 | 76 |
| 2022 10 | 85 | 12 | 97 |
| 2022 9 | 38 | 7 | 45 |
| 2022 8 | 71 | 15 | 86 |
| 2022 7 | 60 | 13 | 73 |
| 2022 6 | 59 | 9 | 68 |
| 2022 5 | 38 | 16 | 54 |
| 2022 4 | 31 | 10 | 41 |
| 2022 3 | 41 | 8 | 49 |
| 2022 2 | 30 | 18 | 48 |
| 2022 1 | 41 | 7 | 48 |
| 2021 12 | 33 | 11 | 44 |
| 2021 11 | 40 | 13 | 53 |
| 2021 10 | 14 | 14 | 28 |
| 2021 9 | 8 | 16 | 24 |
| 2021 8 | 5 | 10 | 15 |
| 2021 7 | 3 | 4 | 7 |
Show all
